news
JAK inhibitors increase risk of cardiovascular problems and cancer, warns PRAC
Janus kinase inhibitors used for chronic inflammatory conditions are only safe for certain patients, advises the EMA’s safety committee.
List view / Grid view
Cardiovascular disease
![Sanofi logo on top of building [Credit: HJBC/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Sanofi-1-300x278.jpg)
![Sanofi logo on top of building [Credit: HJBC/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Sanofi-1.jpg)
news
Sanofi launches Impact® brand of medicines for low-income countries
Sanofi Global Health — a nonprofit unit of Sanofi set up in 2021 — has launched Impact®, a new brand of standard of care medicines dedicated for nonprofit distribution in 40 of the world’s lower-income countries.
article
Data-enriched edible pharmaceuticals (DEEP): a new generation of solid drug products
In this article, Natalja Genina, Ilari Ahola, Johan Bøtker and Jukka Rantanen at the University of Copenhagen and Sofia Kälvemark Sporrong from Uppsala University discuss the potential of data-enriched edible pharmaceuticals (DEEP) to overcome various drug administration and supply challenges.
news
New EFPIA network created to combat cardiovascular diseases
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has initiated the CVD Network to improve policies for patients.
news
NICE recommends Liraglutide for treatment of obesity and non-diabetic hyperglycaemia
Liraglutide (Saxenda) will be offered to adults with non-diabetic hyperglycaemia and a high risk of cardiovascular disease.
article
Effect of COVID-19 on treatment of non-communicable diseases
Coronavirus or COVID-19 is currently the leading cause of mortality worldwide. With a patient database of 4,150,343 active cases (as of 28 June 2020), it is the most hit word on the internet today. Besides this catastrophe, the world has been facing a severe shortage of healthcare facilities, which has…
news
UK vaccine clinical trial outsourcing expansion continues
An outsourcing company has announced that Phase II, III and IV clinical trials of vaccines will continue at a growing number of sites, assessing the safety of each in light of COVID-19.
news
Drug approved which reduces risk of cardiovascular events
The FDA has approved Vascepa (icosapent ethyl) as a secondary therapy to reduce cardiovascular events in adults.
news
Job cuts limit cardiovascular and diabetes research and development
Pharmaceutical company, Sanofi, will eliminate jobs in France and Germany and end new in-house cardiology research programmes.
news
Benzodiazepines could decrease mortality in congestive heart failure
Researchers have suggested that benzodiazepines should be the first course of treatment for those with cardiovascular disease and anxiety...
news
Frequent aspirin use linked to increased bleeding
A study has found that long term aspirin use increases patients' risk of major bleeding events by 43 percent, with 1 in 200 having a major bleed...
news
Increasing dose of statins could save more lives
A study has shown that thousands of heart attacks and deaths caused by cardiovascular disease could be prevented through the use of statins...
news
3D bioprinting technique for artificial organ tissue and arteries
A 3D bioprinting technique could, in the future, allow the creation of human tissue structures for the analysis of various diseases...
news
Manufacturing small batches of biopharmaceuticals on demand
Portable biopharmaceutical drug manufacturers could be the future method of producing the drugs on demand for outbreaks of disease...
news
Statins study questions their widespread use in the healthy elderly
A new observational study has identified no benefit from prescribing statins to healthy pensioners aged over 75 to prevent heart disease...
